


FLAVIO RIZZOLIO

CEO & OTHERS

BIOFUTURE MEDICINE




IDEA-MISSION

- A SORT OF DREAM INSIDE
- A STRUGGLING TIME.....
- WHY NOT?
- APPLIED WHAT WE CURRENTLY PUBLISH ON RESEARCH PAPERS
 - ONLY APPLIED SCIENCE
- HELP WOMEN WITH OVARIAN CANCER



Welcome!



Products



Research



Biomam

RESEARCH

PRODUCTS

2016




RESEARCH

UNIVERSITY OF TRIESTE
UNIVERSITY OF UDINE
UNIVERSITY OF PADUA
UNIVERSITY OF PISA

IMPERIAL COLLEGE LONDON
UNIVERSITY OF ANGERS, FRANCE
ROYAL COLLEGE OF SURGEONS IN
IRELAND, DUBLIN

CANCER, A LETHAL CHRONIC DISEASE



In developed countries, health and well-being are the primary goals for people of all ages.

Data: People in USA

NEED



OVARIAN CANCER

IS THE 5TH DEADLIEST CANCER AMONG WOMEN AND MORE OF 75% OF OVARIAN CANCER PATIENTS ARE DIAGNOSED IN ADVANCED STAGE.




DRUG SCREENING TESTS



PERFORMED ON A PATIENT-SPECIFIC MODEL ARE CURRENTLY MISSING AND COULD HELP DOCTOR TO FIND THE BEST THERAPY FOR THE PATIENT SAVING TIME AND RESOURCES.



THE CURRENT MARKET

- Our target market is ovarian cancer therapy.
- The global therapeutic market for ovarian cancer reached \$2.1 billion in 2017 and is expected to reach **\$2.9 billion** by 2023, with a compound annual growth rate (CAGR) of **11.8%** during the period 2018-2024.
- Currently, there are some clinical studies aiming to determine drug sensitivity in patients using organoids.






Organoids : a revolution?



Ovarian Cancer


Estimated number of incident cases ovary, all ages



Data source: Globocan 2020
Graph production: Global Cancer
Observatory (<http://gco.iarc.fr>)


International Agency for Research on Cancer
World Health
Organization

Global Ovarian Cancer Market



APPLICATION BUSINESS ANALYSIS


Fig.22. Organoids & spheroids market: Application outlook and key takeaways



Source: Industry Journals, Investor Presentations Primary Interviews, Grand View Research


END-USE BUSINESS ANALYSIS

Fig.27 Organoids & spheroids market: End-use outlook and key takeaways



REGIONAL BUSINESS ANALYSIS


Fig.30 Organoids & spheroids market: Regional outlook and key takeaways




Source: U.S. FDA, IPFMA, WHO, industry journals, investor presentations Primary Interviews, Grand View Research

SOLUTIONS

- **We are offering a customized patient-specific drug screening kit, leveraging our ongoing research that has already yielded positive results.**
- **Our team can conduct a comprehensive personalized drug screening within three weeks starting from the biopsy.**



Patient-specific drug effect report



COMPETITIVE EDGE

- ✓ We have the expertise to perform these personalized drug tests.
- ✓ Currently, we are conducting these tests as part of a research program.
- ✓ We have received positive feedback from doctors
- ✓ We already have potential customers interested in this project.



REVENUE STREAMS

ORDERED BY PRIORITY/IMPORTANCE:

B2B


SMEs FOR TARGETED DRUG DEVELOPMENT

HOSPITALS AND MEDICAL CENTERS: FRONTLINE PRODUCTS ARE DEVELOPED TO BE USED BY CLINICIANS. THE MAIN PRODUCTS ARE DIAGNOSTIC KITS FOR CANCER PREVENTION.

B2R


UNIVERSITIES, RESEARCH CENTERS: BACKSTAGE PRODUCTS ARE USEFUL FOR RESEARCHERS WORKING IN TRANSLATIONAL MEDICINE. MODIFIED CANCER CELL LINES, KITS FOR DNA PURIFICATION AND EXTRACTION ARE BASIC REQUIREMENTS FOR MOST LABORATORIES.







—●— Revenue —●— Expenses



KEY COMPETITORS



Products | Services | Resources | Support | About



Explore the new wish list functionality on our website, which lets you organize products into wish lists, view your saved products, and share them with others. Sign in or create an account to access this feature.

Home > Product Portfolios > Organoids > View All

Brands

TeSR™

IntestiCult™

STEMdiff™

PneumaCult™

PancreaCult™

HepatiCult™

Organoids

Perhaps one of the most exciting advances in stem cell research of the past decade has been the development of organoid culture techniques. Organoids are three-dimensional cell cultures that incorporate some of the key features and functions of the represented organ. These versatile model systems have broad applicability and have seen rapid adoption in both basic and industrial research contexts, due to their enhanced relevance to the in vivo organ and the ease with which they can be manipulated in vitro.

Products

FILTER BY: All Human Mouse Non-Human Primate Other Rat

Cell Culture Media and Supplements (32)




Prodotti



Home > Prodotti > Colture e analisi cellulari > Colture cellulari 3D > Organoidi

Organoidi



Gli organoidi sono insiemi complessi di cellule cresciute in un mezzo di coltura 3D in grado di ricapitolare molte delle caratteristiche fisiologiche e genomiche di vari tessuti o organi. Gli organoidi derivano da cellule staminali embrionali (ESC), cellule staminali pluripotenti indotte (iPSC) o cellule staminali adulte (ASC) e si differenziano, attraverso una serie di segnali controllabili, in un insieme diversificato di tipi cellulari simili a quelli che si trovano nei rispettivi tessuti fisiologici.

Una volta stabilite le condizioni di coltura e differenziazione per un particolare tipo di organoide, queste possono essere riprodotte dai ricercatori semplicemente usando le metodiche di base delle colture cellulari. Nello scorso decennio sono stati compiuti moltissimi progressi in questo settore, tra cui la generazione e la caratterizzazione di nuovi tipi di organoidi le cui applicazioni hanno contribuito a far progredire la ricerca biologica di base e lo sviluppo di nuove terapie.

CURRENT STATUS



Dott.
Stavros
Papadimitriou





OUR MISSION

Provide Instruments, Consumables & Services
that Increase Productivity for
Cytogenetic, Pathology, and Molecular Genetics in Clinical
and Research Diagnostic Laboratories




21/03/2022

2



—●— Revenue —●— Expenses



Global Cell Culture Market

2023: 3.3 Eur Billions

2033: 6.4 Eur Billions

CAGR: 7%

THE TEAM

MADE in ITALY

FLAVIO RIZZOLIO, CEO

FOUNDER OF THE COMPANY

PHD IN ONCOLOGY AND GENETICS

HEAD OF NANOMEDICINE LABORATORY AT CA'

FOSCARI UNIVERSITY

Advisory Board

Prof. Tiziano Tuccinardi
Medicinal chemist
Univ. Pisa

Prof. Carlotta Granchi
Organic Chemist
Univ. Pisa

NEW CEO

MADE in ITALY

DOTT. VITALIY LABA

Chartered Accountant & Auditor



- I work in Management Consulting and Strategic Finance, supporting SMEs and Public Entities in the management of R&D projects and innovation funded within the framework of resources such as PON, PO-FESR, FISR, PRIN, etc.
- Member of the Corporate Finance Committee and Structural Funds ODCEC of SIRACUSA.
- Father of Matilde and husband of Marzia.

